AbbVie Receives $20M Milestone in its DUB Targets Collaboration with Mission to Treat Alzheimer and Parkinson Diseases
Shots:
- AbbVie selects two DUB targets to advance it to the next stage of drug discovery based on the results from in vitro & in vivo studies for which Mission will receive a $20M as milestones
- As per 2018 agreement- the companies collaborated to identify novel DUB targets and discover associated inhibitor compounds for neurodegenerative diseases. AbbVie had the option to obtain exclusive rights to develop & commercialize inhibitors of selected DUB targets for which Mission will receive milestones along with royalties for each commercialized product
- DUBs help to maintain cell health & regulates the degradation of proteins including the amyloid-beta and alpha-synuclein molecules
Ref: Mission Therapeutics | Image: abbvie
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
